A Study of Poziotinib in Patients With EGFR or HER2 Activating Mutations in Advanced Malignancies
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
This is a Phase 2, open-label, multicenter study to evaluate the efficacy and the
safety/tolerability of poziotinib in five patient cohorts for up to 150 previously treated
patients with any systemic therapy (Cohort 1: 30 Patients that have HER2-positive or
HER2-negative breast cancer with HER2 activating mutations, Cohort 2: 30 Patients that have
colorectal cancer with HER2 activating mutations, Cohort 3: Patients that have solid tumors
(except NSCLC, breast cancer, or colorectal cancer) with HER2 activating mutations, Cohort 4:
30 Patients that have high-grade glioma with EGFR activating mutations, and Cohort 5: 30
Patients that have solid tumors (except NSCLC or high-grade glioma) with EGFR activating
mutations.